Cargando…

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats

Amyloid-β (Aβ) plaque formation, neuronal cell death, and cognitive impairment are the unique symptoms of Alzheimer's disease (AD). No single step remedy is available to treat AD, so the present study aimed to improve the drugability and minimize the abnormal behavioral and biochemical activiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajkumar, Manickam, Sakthivel, Murugesan, Senthilkumar, Kottaisamy, Thangaraj, Ramasundaram, Kannan, Soundarapandian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058960/ https://www.ncbi.nlm.nih.gov/pubmed/35510084 http://dx.doi.org/10.1016/j.crphar.2022.100100

Ejemplares similares

Drug-Carrying Capacity and Anticancer Effect of the Folic Acid- and Berberine-Loaded Silver Nanomaterial To Regulate the AKT-ERK Pathway in Breast Cancer
por: Bhanumathi, Ramasamy, et al.
Publicado: (2018)

Protective Effect of Acacia nilotica (L.) against Acetaminophen-Induced Hepatocellular Damage in Wistar Rats
por: Kannan, Narayanan, et al.
Publicado: (2013)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study
por: Gajbhiye, Kavita R., et al.
Publicado: (2017)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Antioxidant and toxicological evaluation of Cassia sopherain streptozotocin-induced diabetic Wistar rats
por: Singh, Rambir, et al.
Publicado: (2013)

Antidiabetic Activity of Polyherbal Formulation in Streptozotocin – Nicotinamide Induced Diabetic Wistar Rats
por: Petchi, Rajendran Ramesh, et al.
Publicado: (2014)

Effect of a polyherbal formulation in streptozotocin-induced diabetic nephropathy in wistar rats
por: Reddy, Kanala Somasekhar, et al.
Publicado: (2019)

Ameliorative effect of galantamine on acetic acid-induced colitis in rats
por: Mahdavi, Niloofar-Sadat, et al.
Publicado: (2019)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Hydroxyapatite-Tethered Peptide Hydrogel Promotes Osteogenesis
por: Yu, Hongwen, et al.
Publicado: (2022)

Pharmacological investigations of new galantamine peptide esters
por: Tsvetkova, Dobrina, et al.
Publicado: (2014)

Galantamine as a Treatment Option for Nicotine Addiction
por: Jamali, Qutub
Publicado: (2021)

Nephroprotective effect of Curculigo orchiodies in streptozotocin–nicotinamide induced diabetic nephropathy in wistar rats
por: Singla, Krishan, et al.
Publicado: (2020)

MitoTEMPOL modulates mitophagy and histopathology of Wistar rat liver after streptozotocin injection
por: Virgana, Rova, et al.
Publicado: (2022)

Galantamine protects against lipopolysaccharide-induced acute lung injury in rats
por: Li, G., et al.
Publicado: (2015)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Bhattacharya, Soumee, et al.
Publicado: (2014)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease
por: Reggiani, Angelo M., et al.
Publicado: (2016)

PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow
por: Wake, Rei, et al.
Publicado: (2016)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
por: Nanaki, Stavroula G., et al.
Publicado: (2020)

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
por: Baakman, Anne Catrien, et al.
Publicado: (2022)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
por: Georgieva, Dilyana, et al.
Publicado: (2023)

Cancer Therapeutic Proficiency of Dual-Targeted Mesoporous Silica Nanocomposite Endorses Combination Drug Delivery
por: Murugan, Chandran, et al.
Publicado: (2017)

Morin incorporated polysaccharide–protein (psyllium–keratin) hydrogel scaffolds accelerate diabetic wound healing in Wistar rats
por: Ponrasu, Thangavel, et al.
Publicado: (2018)

Effect of galantamine on platelet functions in healthy elderly people
por: Isik, Ahmet Turan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c029d3nfcbk68589jqduk7pvhf